MoonLake Immunotherapeutics (MLTX)
NASDAQ: MLTX · Real-Time Price · USD
45.82
+2.01 (4.59%)
Jan 21, 2025, 4:00 PM EST - Market closed
MLTX Employees
MoonLake Immunotherapeutics had 50 employees as of December 31, 2023. The number of employees increased by 30 or 150.00% compared to the previous year.
Employees
50
Change (1Y)
30
Growth (1Y)
150.00%
Revenue / Employee
n/a
Profits / Employee
-$1,615,362
Market Cap
2.89B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 50 | 30 | 150.00% |
| Dec 31, 2022 | 20 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novartis AG | 76,057 |
| Merck & Co. | 72,000 |
| Novo Nordisk | 64,319 |
MLTX News
- 4 days ago - MoonLake Immunotherapeutics: Mid-2025 Sonelokimab HS Data Could Be Enhanced Upon - Seeking Alpha
- 13 days ago - MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab - GlobeNewsWire
- 4 months ago - MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11 - GlobeNewsWire
- 6 months ago - MoonLake Immunotherapeutics: Second Late-Stage Program Moves Sonelokimab Forward - Seeking Alpha
- 8 months ago - MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa - GlobeNewsWire
- 9 months ago - MoonLake Immunotherapeutics' Competitive Edge In Autoimmune Market Expansion - Seeking Alpha
- 9 months ago - MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update - GlobeNewsWire
- 10 months ago - MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions - GlobeNewsWire